On the basis of these findings, UK Interim clinical commissioning policy and COVID-19 treatment guidelines published by National Institutes of Health USA recommended the use of tocilizumab in combination with dexamethasone in certain hospitalized patients who are exhibiting rapid respiratory decompensation or requires supplemental oxygen with a CRP level of at least 7.5 mg/dL due to COVID-19 (32, 33). This evidence concerns the gene CRP and COVID-19.